News

COR588, Quince Therapeutics’ investigational oral small molecule for mild to moderate Alzheimer’s disease, appears to be safe and well tolerated, according to results from a Phase 1 trial, the company announced. (The company was known as Cortexyme until Aug. 1.) The recently completed single and multiple ascending dose clinical…

Treatment with Alzheon‘s oral candidate ALZ-801 (valiltramiprosate) lowered levels of a key biomarker for Alzheimer’s disease — and led to significant memory improvements in people with the neurodegenerative disorder. That’s according to data from a six-month interim analysis of an ongoing Phase 2 biomarker…

Chronic treatment with HT-ALZ, Hoth Therapeutics‘ investigational oral therapy for Alzheimer’s disease, led to significant cognitive improvements in a mouse model of the neurodegenerative condition. The data were collected as part of Hoth’s ongoing sponsored research agreement with investigators at Washington University in St. Louis, Missouri, led by…

Cannabis researcher MedPharm has been granted funding to study the effect of phytocannabinoids — naturally occurring chemicals, called cannabinoids, from marijuana plants — on Alzheimer’s disease, with the ultimate aim of treatment development. The new funding comes from the Colorado State University Institute of Cannabis Research (ICR). It was…

The first patient has been dosed in an open-label dose optimization trial of bryostatin, an investigational treatment for Alzheimer’s disease. According to the therapy’s developer, Synaptogenix — previously called Neurotrope — the dose-finding trial will prepare the company to move forward with bryostatin’s next phase of clinical…

The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to Elecsys Amyloid Plasma Panel, Roche’s blood-based biomarker test designed to enable earlier Alzheimer’s disease diagnoses. Breakthrough device designation is granted to medical devices that provide a more effective way of treating or diagnosing a life-threatening…

Assisted Living Locators, a nationwide placement and referral service for seniors, is again set to support the Walk to End Alzheimer’s, touted as the world’s largest event to raise awareness and funds for Alzheimer’s disease care, support, and research. The event is presented by the Alzheimer’s Association…

Residents in the Dallas/Fort Worth area of Texas will be among the first to have access to a minimally invasive diagnostic test for Alzheimer’s disease. The DISCERN test, by SYNAPS Dx (SDx), will be commercially launched in Texas because of the state’s relatively high number of people…

A large clinical trial has received $45 million in U.S. funding to evaluate the efficacy of benfotiamine — a lab-made precursor of thiamine or vitamin B1 — in slowing the cognitive decline of those with mild Alzheimer’s disease or mild cognitive impairment. The five-year grant was awarded by the…

Repeated dosing of ACD856, an investigational therapy for Alzheimer’s disease, was generally safe and well tolerated in healthy adult volunteers, according to data from a now-completed Phase 1 trial. AlzeCure Pharma is developing ACD856 as its lead therapeutic candidate in the company’s NeuroRestore platform, which contains investigational therapies for…